6.5 Product Tampering & Alteration: Physical Detection

6.5 Product Tampering & Alteration: Physical Detection

Quick Answer: The blueprint line "signs of product tampering and/or alteration (e.g., vial tops that don't twist easily, chipped tablets, drug assay sampling)" is testing hands-on inspection, not laboratory chemistry. Tampering is the diversion mechanism that has caused every major healthcare hepatitis C outbreak, so the exam expects a technician to recognize a reseated flip-off cap, a punctured septum, a re-flamed ampule neck, a chipped or mismatched tablet, and a compromised prefilled syringe — and to quarantine and escalate rather than test, clean, or restock.

---

Where to Look: Inspection Points Along the Chain

---

Vials: The Highest-Yield Signs

An intact single-dose or multi-dose vial has an aluminum crimp seal with a plastic flip-off disc. Factory assembly means the disc lifts away with light thumb pressure and the crimp is uniform. A diverter who removes contents must get past that seal and then make the vial look untouched.

Ampules carry their own signature: a flame-sealed neck that has been opened and re-sealed shows a bulbous, discolored, or asymmetric tip, sometimes with carbon deposits; the score ring may be missing or abraded; fine hairline cracks may be visible when rotated against light; and the fill volume sits below the marked line.

Prefilled syringes and cartridge units (carpujects) show: a torn or missing tamper-evident tip seal, a plunger displaced from the shipped position, a volume that does not match the labeled fill, a cap that has been refitted at an angle, and label edges lifted where the unit was re-sleeved.

---

Oral Solids: Chipped Tablets and Substitution

The blueprint names chipped tablets specifically because partial removal and look-alike substitution are the dominant oral-solid mechanisms:

• Chipped, split, scraped, or shaved tablets, and loose powder or dust at the bottom of an otherwise clean bottle.
• Imprint, score, color, size, or coating mismatch within a single bottle — the classic substitution of an over-the-counter analgesic for an opioid of similar appearance.
• Capsules that have been opened and reassembled — misaligned bands, a loose fit, or contents of a different color or texture.
• Broken or re-applied induction (foil) seal, wrinkled or re-glued, or a seal that shows two adhesive rings.
• Cotton removed, replaced upside down, or absent from a bottle that should be factory-packed with it.
• Count discrepancies that recur on the same fast-mover while the perpetual record balances.
• Blister packs with a resealed foil backing, a bubble opened from the back, or a unit-dose package with a heat-seal line that does not match its neighbors.

Transdermal fentanyl patches deserve a separate line: signs include a cut, slit, or pinhole in the backing, gel absent or redistributed, a pouch that has been opened and re-sealed with adhesive or heat, weight below the expected range, and used patches that are missing from the return-and-count log. Patch accountability is count-in/count-out with return of the used patch.

Infusion bags and PCA cassettes: puncture marks in the port or bag body, a re-spiked or double-spiked port, an unexplained gap between the delivered volume and the pump's volume-to-be-infused, weight inconsistent with the labeled volume, and a bag that appears newly hung before its calculated completion time.

---

Drug Assay Sampling Programs

The blueprint's third example — drug assay sampling — refers to a structured program rather than one-off testing. A defensible program specifies:

1. Scope and population. Which products and locations are sampled: high-risk injectables in the OR, PACU, cath lab, and endoscopy; returned waste syringes; returned unadministered doses; and any unit flagged by analytics.
2. Sampling design. A defined random sample of waste or returns on a fixed cadence, plus for-cause sampling triggered by an analytics alert or a peer report. Random sampling is what creates deterrence; for-cause sampling is what builds a case.
3. Method tiers. Point-of-care screening — handheld optical or digital refractometry and immunoassay test strips — for immediate presence and concentration checks; confirmatory laboratory analysis — HPLC, GC-MS, or LC-MS/MS — for the definitive molecular identification required in employment or criminal proceedings. Gravimetric weight screening supplements both.
4. Chain of custody. Every sample is sealed in serialized tamper-evident packaging, logged with collector, date, time, location, and every subsequent custodian, and transferred with signatures at each hand-off (Section 6.3).
5. Result handling. Predefined thresholds, escalation to the MDRT, and a documented disposition for both confirmed and cleared results.

---

The Containment Algorithm

┌──────────────────────────────────────────────────────────────────────────────┐
│              SUSPECTED TAMPERED UNIT — IMMEDIATE ACTIONS                     │
│                                                                              │
│  1. STOP. Do not administer. Do not return to inventory.                     │
│  2. DO NOT wipe, decant, open, smell, field-test, or photograph-and-handle.  │
│     Minimize handling to preserve prints, DNA, and residue.                  │
│  3. QUARANTINE the unit AND its lot/pocket/carton — tampering is rarely      │
│     limited to one container.                                                │
│  4. PACKAGE in a serialized tamper-evident evidence pouch; start the         │
│     chain-of-custody log (collector, date/time, location, witness).          │
│  5. NOTIFY: pharmacy leadership → MDRT → security → risk management.         │
│  6. ESCALATE CLINICALLY: infection prevention and employee health, because   │
│     injectable tampering can transmit bloodborne pathogens.                  │
│  7. PRESERVE the surrounding evidence: ADC transaction logs, badge access,   │
│     video for the pocket and the return bin, staffing assignments.           │
│  8. DETERMINE PATIENT EXPOSURE: was any unit from this lot administered?     │
│     Initiate look-back and patient notification per risk management.         │
│  9. REPORT externally as indicated: DEA (theft/significant loss → Section    │
│     5.6), state boards, law enforcement, FDA MedWatch and the manufacturer   │
│     if a product-integrity defect cannot be excluded.                        │
└──────────────────────────────────────────────────────────────────────────────┘

The single most common wrong answer on this topic is "return the vial to stock and monitor." A suspected tampered unit never re-enters inventory, and it is never handled casually — it is simultaneously a patient-safety hazard, a potential infectious exposure, and criminal evidence.

---

Why Physical Detection Still Matters in an Analytics Era

Statistical surveillance detects transaction patterns; it cannot see a reseated cap. In the landmark outbreaks covered in Section 2.3, the diverters' transaction footprints were unremarkable because they were stealing product that was already dispensed and staged. What actually stops that mechanism is a nurse who notices the flip-off cap will not twist, a technician who spots two lot numbers in one sealed carton, and a witness who sees that the waste syringe is thinner and clearer than fentanyl should be. Physical inspection and drug assay sampling are the controls that close the gap analytics leaves open — which is exactly why the blueprint lists them by name.